YOLFTbeta
Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc.

RNAC · NASDAQ · Healthcare / Biotechnology

6.35USD-0.01 (-0.08%)

Price History

Full chart

Market Stats

Previous Close6.36
Open6.39
Day Range6.16 – 6.40
52-Week Range5.60 – 11.00
Volume106.82K
Market Cap224.19M
P/E (TTM)0.00
Forward P/E25.06
EPS-5.78
Dividend Yield0.00%
Beta0.62
50-Day Avg8.63
200-Day Avg7.74

About

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Carsten Brunn Ph.D.
  • Employees75
  • Headquarters7495 New Horizon Way, Frederick, MD, United States, 21703, USA
  • Websitehttps://www.cartesiantherapeutics.com

Leadership

  • Dr. Carsten Brunn Ph.D.President, CEO & Chairman of the Board · b. 1971
  • Mr. Blaine T. DavisChief Financial Officer · b. 1974
  • Dr. Emily English Ph.D.Chief Operating Officer · b. 1980
  • Ms. June SeymourChief Accounting Officer · b. 1978
  • Mr. Matthew Bartholomae J.D.General Counsel & Secretary
  • Dr. Peter G. Traber M.D.Head of R&D · b. 1955

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.04M6.01M8.08M207.00K903.00K6.68M16.60M85.08M110.78M26.00M38.91M2.80M
Growth (%)-+97.73%+34.47%-97.44%+336.23%+639.42%+148.57%+412.60%+30.21%-76.53%+49.64%-92.81%
Cost of Revenue17.57M14.59M15.30M45.16M47.69M42.74M--2.04M1.55M--
Gross Profit3.04M6.01M8.08M207.00K903.00K6.68M16.60M85.08M108.74M26.00M38.91M2.80M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%98.16%100.00%100.00%100.00%
Operating Expense18.44M31.32M42.75M63.99M65.92M59.13M73.42M89.67M94.20M112.42M82.81M89.50M
Operating Income-15.40M-25.30M-34.67M-63.78M-65.02M-52.45M-56.82M-4.60M14.54M-86.42M-43.90M-86.70M
Operating Margin-506.55%-420.96%-428.92%-30813.53%-7200.66%-785.61%-342.36%-5.40%13.12%-332.32%-112.81%-3099.93%
EBITDA-11.46M-23.18M-34.16M-63.37M-62.87M-51.80M-65.59M-5.16M39.84M-235.03M-75.99M-136.54M
EBITDA Margin-377.11%-385.66%-422.55%-30611.11%-6962.02%-775.86%-395.21%-6.06%35.96%-903.84%-195.27%-4881.52%
Net Income-12.88M-25.17M-36.21M-65.32M-65.34M-55.35M-68.88M-25.69M35.38M-219.71M-77.42M-130.30M
Net Income Margin-423.68%-418.80%-447.98%-31556.04%-7235.44%-828.97%-414.99%-30.19%31.94%-844.91%-198.97%-4658.63%
R&D10.49M22.98M29.70M45.16M47.69M42.74M54.51M68.74M72.38M71.26M45.10M58.03M
R&D as % of Total Revenue344.93%382.30%367.46%21818.84%5280.95%640.15%328.40%80.79%65.34%274.03%115.91%2074.87%
Interest Expense552.00K948.00K1.25M1.21M1.49M1.52M1.56M2.84M3.03M2.83M0-
Interest Expense % of Total Revenue18.16%15.77%15.50%582.61%165.45%22.75%9.38%3.34%2.74%10.89%0.00%-

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets22.23M42.82M89.30M101.10M44.48M99.57M165.44M159.88M165.89M305.05M435.02M296.41M
Total Liabilities109.98M159.32M34.34M49.29M49.90M91.17M183.44M137.36M72.06M745.23M441.82M422.65M
Total Equity-87.75M-116.49M54.96M51.81M-5.42M8.40M-18.01M22.52M93.83M-440.18M-6.80M-126.24M
Cash16.59M32.34M58.66M70.70M37.40M90.17M138.69M114.06M106.44M76.91M212.61M125.14M
Total Debt7.40M15.23M12.04M21.04M21.39M19.28M35.35M35.28M37.92M10.96M13.98M12.68M
Net Debt-9.19M-20.48M-46.61M-49.66M-16.02M-70.89M-103.34M-78.78M-68.51M-65.96M-198.63M-112.46M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.69M-22.46M-19.68M-52.04M-59.16M-51.44M34.88M-60.38M-31.63M-51.16M-23.67M-73.94M
Investing Cash Flow-227.00K-4.68M-22.10M-2.10M25.27M229.00K-741.00K-17.14M-15.00M34.61M-8.74M-5.45M
Financing Cash Flow24.77M43.91M67.66M66.02M697.00K105.04M14.43M52.90M39.22M-13.14M168.43M-8.05M
Capital Expenditure227.00K1.16M586.00K733.00K884.00K47.00K815.00K1.08M1.20M206.00K9.09M5.45M
Free Cash Flow-12.91M-23.63M-20.27M-52.77M-60.05M-51.48M34.07M-61.47M-32.83M-51.37M-32.77M-79.39M
Dividends Paid--4.57M25.45M-28.00K184.00K-----
FCF to OCF101.79%105.18%102.98%101.41%101.49%100.09%97.66%101.80%103.80%100.40%138.41%107.38%
Dividend Paid to FCF---22.53%-48.23%--0.05%0.54%-----

Earnings

Report DateAug 9, 2016Nov 10, 2016Mar 27, 2017May 11, 2017Aug 11, 2017Nov 7, 2017Mar 15, 2018May 9, 2018Aug 8, 2018Nov 8, 2018Mar 15, 2019May 9, 2019Aug 8, 2019Nov 8, 2019Mar 12, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Mar 11, 2021May 13, 2021Aug 12, 2021Nov 9, 2021Mar 10, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 2, 2023May 4, 2023Aug 17, 2023Nov 13, 2023Mar 7, 2024May 8, 2024Aug 8, 2024Nov 7, 2024Mar 5, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Mar 9, 2026Apr 30, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-0.47-0.42-0.25-1.28-0.90-0.87-0.56-0.54-0.68-0.75-0.70-0.35-0.30-0.33-0.21-0.28-0.010.06-0.12-0.12-0.12-0.07-0.07-0.11-0.08-0.01-0.07-0.09-0.08-0.06-0.04-1.42-0.09-0.55-0.83-0.71-0.76-0.63-0.79-0.70-0.83-1.02
EPS Actual-2.75-0.43-0.77-0.82-0.85-0.63-0.88-0.71-0.84-0.71-0.65-0.31-0.37-0.26-0.30-0.21-0.25-0.09-0.14-0.220.04-0.160.030.230.06-0.050.04-0.14-0.07-0.06-0.07-0.800.64-0.42-0.59-0.650.50-0.73-2.71-0.950.46-
Surprise-485.11%-2.38%-208.00%35.94%5.56%27.59%-57.14%-31.48%-23.53%5.33%7.14%11.43%-23.33%21.21%-42.86%25.00%-2400.00%-250.00%-16.67%-83.33%133.33%-128.57%142.86%309.09%175.00%-400.00%157.14%-55.56%12.50%0.00%-75.00%43.66%811.11%23.64%28.12%8.45%165.79%-15.87%-242.59%-35.71%155.42%-
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap224.19M
Enterprise Value154.36M
Trailing P/E0.00
Forward P/E25.06
PEG Ratio0.00
Price / Sales151.79
Price / Book31.26
EPS-5.78
Book Value-4.17
Revenue (TTM)1.48M
Gross Profit (TTM)-66.91M
EBITDA-96.05M
Profit Margin0.00%
Operating Margin-6679.69%
Return on Equity-7029.26%
Return on Assets-17.43%
Shares Outstanding30.26M
Shares Float11.49M
Beta0.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 8 analystsTarget 33.67
  • Strong Buy
    4
  • Buy
    2
  • Hold
    2

Ownership Breakdown

Institutions
29.45%
Insiders
52.13%
Retail / Other
18.42%

Top Institutional Holders

  • Squarepoint Ops LLC
    2.24M7.40%
  • FMR Inc
    799.74K2.64%
  • BlackRock Inc
    599.11K1.98%
  • Vanguard Capital Management, LLC
    407.60K1.35%
  • 683 Capital Management LLC
    330.00K1.09%
  • Millennium Management LLC
    309.89K1.02%
  • Two Sigma Investments LLC
    296.29K0.98%
  • Geode Capital Management, LLC
    263.69K0.87%
  • Marshall Wace Asset Management Ltd
    251.12K0.83%
  • Erste Asset Management GmbH
    221.71K0.73%
  • State Street Corp
    200.34K0.66%
  • Privium Fund Management B.V.
    179.11K0.59%
  • UBS Group AG
    136.84K0.45%
  • Jacobs Levy Equity Management, Inc.
    101.53K0.34%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    376.31K1.24%
  • Fidelity Select Biotechnology
    366.55K1.21%
  • iShares Russell 2000 ETF
    333.54K1.10%
  • Janus Henderson Small Cap Gr Alpha ETF
    195.16K0.65%
  • Fidelity Small Cap Index
    142.99K0.47%
  • iShares Russell 2000 Value ETF
    93.86K0.31%

Stock Splits

  • Apr 5, 20241:30